intravitreal injection of infliximab
Phase 1Monoclonal antibody
intravitreal injection of infliximab is one of 23 small molecule programs targeting Choroidal Neovascularization. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
25 competitors in Choroidal Neovascularization
#DrugCompanyPhaseTrials
1Visudyne
BBausch Health Americas, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Avastin
BBio-Thera Solutions
Phase 3
Verteporfin PDT
NovartisPhase 3
Vabysmo
RochePhase 2
Intravitreal Bevacizumab
AAsociación para Evitar la Ceguera en México
Phase 3
Intravitreal Injection of Avastin
SShahid Beheshti University of Medical Sciences
Phase 3
Macugen
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 1[1]
- Company
- RRetina Research Foundation